ReviewFrontiers in immunology2025
Clinicopathological characteristics and treatment patterns of combined small-cell lung cancer: a real-world single-center study with a mini review.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and internal validation of dynamic nomograms for predicting recurrence and survival in patients with resected combined small cell lung cancer.Journal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Combined small-cell lung cancer is a rare subtype of SCLC, which is characterized by the coexistence of SCLC with any histological type of non-small cell lung cancer. There is limited clinical data. We aimed to explore the clinicopathological features and prognosis of C-SCLC patients who received anti-tumor therapy. Methods: Eligible patients were histopathologically confirmed adult C-SCLC who received anti-tumor treatment at Sir Run Run Hospital. This analysis aimed to describe the clinicopathological characteristics and evaluate the tumor response rate (RR), disease control rate (DCR), and progression-free survival (PFS). Results: Thirty patients were included. Eighty-three point three three percent were male, and sixty-six point six seven percent were non-smokers. Squamous cell carcinoma (SCC; 11/30) and adenocarcinoma (AC; 11/30) were the most frequently observed mixed components, followed by large-cell neuroendocrine carcinoma (LCNEC; 8/30). Patients received immunochemotherapy (13/30), platinum-based chemotherapy (9/30), or anti-EGFR-/anti-VEGF-based therapy (8/30). Most patients used the anti-PD-1 inhibitor Serplulimab (n=7). Among 27 patients with measurable disease, the RR and DCR were 51.85% (95% CI: 31.95 - 71.33%) and 85.19% (95% CI: 66.27 - 95.81%), respectively. The median PFS was 9.70 months (95% CI: 4.37 - 18.73). The median PFS of C-SCLC mixed with LCNEC was higher than that of those mixed with AC or SCC (10.62 Conclusion: Our findings provide a basis for systematic treatment strategies in C-SCLC and suggest that patients may derive benefit from immunotherapy, although further studies are needed to confirm these observations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.